Since late 2024, we have been aligned with ABL, Inc. Together we offer scalable support for specialty advanced therapeutic developers from research to commercialization with United States and European locations.
Ascend can support your journey at any scale for:
Gene therapies
Immunotherapies
Oncolytics
Vaccines
Development Based Expertise
All our work comes from a background of developing therapies. When we struggled to find our own CDMOs, we became one. Discover the difference of working with a team with deep chemistry, manufacturing & controls (CMC).
Decades of Biologics, Innovation & Expertise
60+ years custom biologics & vaccines support with 20+ AAV development expertise
Next gen technologies & analytics complemented by deep regulatory acumen
Onsite fill-finish capabilities in multiple US locations
Latest News & Insights
18 May 2026
Mind the Loss: Formulation optimization reduces cannula-associated vector loss during precision AAV brain delivery
In this poster presented at ASGCT 2026, Philipp Beck explores how formulation optimization can reduce vector loss during direct...
Read More18 May 2026
Lentiviral Vector Purification: Optimizing the Downstream Chromatography Step
In this presentation from ASGCT 2026, Shanshan Zhu shares new insights into optimizing anion exchange chromatography for lentiviral vector...
Read More18 May 2026
Not all reads are created equal: correcting the size bias in rAAV nanopore sequencing data
In this presentation from ASGCT 2026, Kathrin Breunig explains how Ascend is improving the accuracy of Oxford Nanopore sequencing...
Read More25 March 2026
Why learning from past mistakes is more important than ever
In this presentation, we explore why gene therapy must learn from its past to unlock its future. Drawing on...
Read MoreTake your career to a new level with Ascend
Email us at hello@www.ascend-adv.com to share your enthusiasm and expertise and one of our team will be in touch.